Drugs / A2/4-1BBL melanoma vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01898039 | May 2013 → Apr 2027 expected | melanoma | Hadassah Medical Organization | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A2/4-1BBL melanoma vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01898039 ↗ |
| Modality | Vaccine | “A2/4-1BBL melanoma vaccine” NCT01898039 ↗ |